I. Eligibility

1. Patient is enrolled in Texas Medicaid and is greater than or equal to 18 years of age.
2. Patient has a diagnosis of chronic hepatitis C virus (HCV) with a confirmed genotype of 1a, 1b, 2, 3, 4, 5, or 6. Genotype test results must be obtained within the previous 5 years from the date of prior authorization request.
3. Immediate treatment is assigned the highest priority for patients with advanced fibrosis (Metavir stage F3) or cirrhosis (Metavir stage F4), liver transplant recipients, and patients with hepatocellular carcinoma. Patients with Metavir scores less than stage 3 may not be approved.
4. Prescriber should be a Board Certified Gastroenterologist, Hepatologist, or Infectious Disease physician. A prescriber other than the above specialists may prescribe and assume responsibility and care for the patient when the prescriber is supervised by a specialist, or with consult from a specialist from the previous 90 days. A copy of written consult must be submitted. Exceptions may be considered when a specialist is not available.
5. Required laboratory values in Section 3 of the prior authorization form must be obtained within 90 days prior to the request for HCV treatment.
6. Q80K polymorphism testing is required for requests for treatment with Olysio within the previous 2 years.
7. NS5A resistance testing is required for requests for treatment with Daklinza or Zepatier in genotype 1a patients within the previous 2 years.
8. Child-Turcotte-Pugh Score must be assessed within 90 days prior to the request for HCV treatment.
9. Female patients’ pregnancy status must be determined by a pregnancy test prior to the request for HCV treatment. The pregnancy test should be conducted as close to the start of treatment as possible, but no later than 90 days prior to the request. Pregnancy status must be confirmed negative for all ribavirin containing regimens. Pregnancy status is not required for age greater than 50, or for those documented as not able to become pregnant.
10. Patient must have one drug screening within 90 days prior to the request for HCV treatment.
11. Patient must be assessed for hepatitis B coinfection within 90 days prior to the request for HCV treatment.
12. Prescriber must provide required lab results at baseline, and treatment weeks 4 and 12.
13. Documentation of any additional supporting labs must be provided if requested by the patient’s health care plan.

II. Treatment approval

1. Prior authorization is granted for 6 weeks per approval. A request using the Antiviral Agents for Hepatitis C Virus Prior Authorization Form-Refill Request should be submitted by 6 weeks, and every 6 weeks thereafter of therapy to facilitate continuation of therapy.
2. Prescriptions may be dispensed for a maximum 28 day supply.
3. Refill authorization is subject to approval based upon submission of labs at weeks 4 and 12. Request for refill prior authorization may be rejected if patient or prescriber are unable to provide the required labs.
4. Request for products other than a preferred product will require additional justification, including rational for why a preferred product is not indicated for the patient. Request for a product other than a preferred product does not guarantee approval.

### Preferred Hepatitis C Agents

<table>
<thead>
<tr>
<th>Direct Acting Antiviral</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daklinza (daclatasvir)</td>
<td>PEG-Intron (peginterferon alfa-2b)</td>
</tr>
<tr>
<td>Epclusa (sofosbuvir/velpatasvir)*</td>
<td>ribavirin capsule/tablet</td>
</tr>
<tr>
<td><em>Epclusa is preferred for genotypes 2 and 3 only</em></td>
<td></td>
</tr>
<tr>
<td>Technivie (ombitasvir/paritaprevir/ritonavir)</td>
<td></td>
</tr>
<tr>
<td>Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir)</td>
<td></td>
</tr>
<tr>
<td>Viekira XR (ombitasvir/paritaprevir/ritonavir and dasabuvir)</td>
<td></td>
</tr>
</tbody>
</table>

### Non-Preferred Direct Acting Antivirals

| Harvoni (sofosbuvir/ledipasvir), Olysio (simeprevir), Sovaldi (sofosbuvir), Zepatier (elbasvir/grazoprevir) | |

---

*SCP-10095-17*
5. Daklinza is indicated for genotypes 1 and 3 in combination with Sovaldi (sofosbuvir), with or without ribavirin. Sovaldi is a non-preferred product and may not be approved in situations where a preferred product is appropriate. Therefore, use of Daklinza with Sovaldi will be limited to consideration for approval only in circumstances when another preferred product is not indicated.

6. Regimen approval is based on genotype, disease related conditions, concurrent drug therapies, and previous HCV treatment regimens.

7. Clients who transition to Medicaid from another health care plan while currently undergoing active HCV treatment will be allowed to continue the HCV treatment regimen without interruption regardless of drug status (preferred or non-preferred).

8. Prescriber and patient must review and sign the Prescriber Certification document.

9. Submission of incomplete or missing forms may result in denial of the request.

III. Additional Considerations

1. Patient’s non-adherence to therapy for more than 14 days may result in discontinuation of prior authorization and additional refills may not be approved. Exceptions are considered in circumstances that are beyond patient or prescriber control. Documentation stating reason for gaps in therapy may be required at the request of the health plan.

2. Patients requiring retreatment will be assessed for approval on a case by case basis.

3. Lost or stolen medications may not be replaced.

4. For appeals and reconsiderations, dates of any test and/or laboratory results that fall outside of the required windows for submission will be considered valid if the date of the test and/or laboratory results were within the required window for submission at the time of the initial HCV prior authorization request. This policy is not applicable if more than 90 days have passed since the initial HCV prior authorization request.

5. HCV viral load is recommended at 12 weeks following completion of therapy. Prescribers should obtain and maintain records of viral load at 12 weeks after completion of therapy.
Prescriber Certification: Patient Education for Hepatitis C Treatment

Please sign and fax to (866) 617-8864 with the Antiviral Agents for Hepatitis C Virus Prior Authorization Form-Initial Request. Please read the Hepatitis C Prior Authorization Criteria and Policy prior to signing this document.

As the prescriber I agree to provide verbal and written educational information about chronic hepatitis C virus (HCV) and current treatment options, including but not limited to the following:

Prevention of HCV re-infection and human immunodeficiency virus (HIV) transmission

- Patients should abstain from injection drug use.
- Other methods of transmission, include needle sharing, sex with infected partners, sharing personal items that might have blood on them such as razors or toothbrushes, or exposure to infected blood and body fluids via cuts or sores on the skin.

Prevention of liver disease progression

- HCV-positive persons should be advised to avoid alcohol because it can accelerate liver disease. Abstinence from alcohol and, when appropriate, interventions to facilitate cessation of alcohol consumption should be advised for all persons with HCV infection.
- The CDC recommends Hepatitis A and B vaccines as well as a yearly influenza vaccine for those with HCV infection. [http://www.cdc.gov/vaccines/schedules/](http://www.cdc.gov/vaccines/schedules/)
- Cases of hepatitis B virus (HBV) reactivation have been reported in HCV/HBV coinfected patients. Patients should be assessed for HBV reactivation at regular intervals, but no more frequently than every 4 weeks.
- Take only medications approved by a health care professional. Prescription drugs as well as over the counter medications and herbal medicines may cause further damage to the liver.
- A buildup of fat in the liver can cause further liver damage. Eating healthy and working out can help patients lose weight and maintain a healthy weight. HCV infected persons who are overweight or obese should be counseled regarding strategies to reduce weight and improve insulin resistance via diet, exercise, or medical therapies.

Drug treatment process

- Patient should provide accurate contact information with a secondary contact for backup.
- Patient is expected to return for laboratory tests at predetermined intervals.
- Adherence to the drug regimen is critical to successful treatment. Medicaid may deny a refill or authorization request due to failure to refill the medication in a timely manner, defined as a refill that is greater than 14 days late. Failure to comply with therapy may result in treatment denial.
- Appropriate education regarding dosage administration, missed doses, food affects, side effects and adverse events related to selected treatment regimen, and therapy duration must be provided prior to treatment initiation.
- Pregnancy is contraindicated during treatment with regimens containing ribavirin. Women of childbearing age should be counseled not to become pregnant while receiving ribavirin-containing regimens, and for up to 6 months after stopping. Two methods of contraception are recommended during drug treatment. Estrogen based therapies may be contraindicated. Estrogen therapy should be replaced with progestin therapy if appropriate.
- HCV infected persons should check with a health care professional before taking any new prescription drug, over the counter drugs, or herbal or nutritional supplements to monitor for potential drug interactions.

Additional information

- Prescriber agrees to provide supporting documentation for any information on the prior authorization form if requested by patient's health plan, provided the request is in compliance with HIPAA.
- Failure to provide required labs or requested documents may result in treatment denial.
Patient support programs

Patient support programs offer various levels of support throughout HCV treatment and some, after treatment completion. These programs are supported by drug manufacturers, and are run independently of Texas Medicaid. Patients may obtain benefit from enrolling in the program specific to the patient's drug regimen.

- Abbvie
  - Website: www.viekira.com/proceed-program
  - Phone: 1-844-2proceed (1-844-277-6233)
- Bristol-Myers Squibb
  - Website: www.patientsupportconnect.bmscustomerconnect.com
  - Phone: 1-844-44-Connect (1-844-442-6663)
- Gilead
  - Website: http://www.mysupportpath.com/
  - Phone: 1-855-7-MYPATH (1-855-769-7284)
- Merck
  - Website: www.zepatier.com/c-ahead/
  - Phone: 866-251-6013

Prescriber acknowledgment

By signing below, I agree that I have explained the contents of this document, provided written and verbal education to the patient, and answered any questions the patient may have regarding their Hepatitis C treatment.

Prescriber Signature: ___________________________ Date ______________

Prescriber Printed Name: ___________________________

Patient acknowledgment

By signing below, I agree that the doctor has explained the contents of this letter and answered any questions I have regarding my Hepatitis C treatment.

Patient Signature: ___________________________ Date ______________

Patient Printed Name: ___________________________
HEPATITIS C
PREAUTHORIZATION REQUEST
PRESCRIBER FAX FORM

ONLY the prescriber may complete and fax this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for preauthorization consideration. For formulary information and to download additional forms, please visit www.bcbstx.com/medicaid

PATIENT INFORMATION

<table>
<thead>
<tr>
<th>Patient Name (First)</th>
<th>Last</th>
<th>Today’s Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>M: DOB (mm/dd/yy):</td>
</tr>
<tr>
<td>Patient Address:</td>
<td></td>
<td>Patient Telephone:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>City, State, Zip:</td>
</tr>
</tbody>
</table>

INSURANCE INFORMATION

<table>
<thead>
<tr>
<th>BCBS ID Number:</th>
<th>Group Number:</th>
</tr>
</thead>
</table>

PRESCRIBER/CLINIC INFORMATION

<table>
<thead>
<tr>
<th>Prescriber Name:</th>
<th>Prescriber NPI#:</th>
<th>Specialty:</th>
<th>State License:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinic Name:</td>
<td>Clinic Address:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>City, State, Zip:</td>
<td>Phone #:</td>
<td>Secure Fax #:</td>
<td></td>
</tr>
<tr>
<td>Name of Consulting/Supervising Physician (if applicable):</td>
<td>Phone #:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST

<table>
<thead>
<tr>
<th>Patient’s Diagnosis- ICD code plus description:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender: ☐ Male  ☐ Female</td>
</tr>
</tbody>
</table>

Initial Requests:

Please complete and fax all required documents to (877) 243-6930 for initial prior authorization requests. Prior authorization will be granted for 6 weeks duration. Labs are required for weeks 0, 4, and 12 of therapy. For refill authorizations please refer to the Prior Approval Refill Request section beginning on page 8 of this fax form.

1. Laboratory (Results below must be from the previous 90 days)

<table>
<thead>
<tr>
<th>Laboratory Test</th>
<th>Value</th>
<th>Date</th>
<th>Laboratory Test</th>
<th>Value</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline HCV RNA level</td>
<td>INR</td>
<td></td>
<td>ALT</td>
<td>HCT</td>
<td></td>
</tr>
<tr>
<td>AST</td>
<td>Hgb</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AlkPhos</td>
<td>RBC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CrCl</td>
<td>Plt</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCr</td>
<td>Albumin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total bilirubin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. Current Patient Status: (check all that apply):

☐ Hepatocellular carcinoma  ☐ HIV co-infection
☐ Awaiting liver transplant  ☐ Null responder
☐ Previous liver transplant(s)  ☐ Partial Responder
☐ Compensated cirrhosis  ☐ Relapsed
☐ Decompensated cirrhosis  ☐ End stage renal disease requiring hemodialysis
☐ Hepatitis B co-infection

A. If the patient has been previously treated for HCV, is the previous treatment regimen(s) known? ☐ Yes  ☐ No  ☐ N/A

If yes, list medications used and any known dates of treatment. ___________________________________________________________
3. Additional Required Information:

A. HCV Genotype: *(Results must be from previous 5 years)*

- [ ] 1a  [ ] 1b  [ ] 2  [ ] 3  [ ] 4  [ ] 5  [ ] 6  
  Date of Testing: ______________

B. Metavir Fibrosis Stage:

- [ ] 0  [ ] 1  [ ] 2  [ ] 3  [ ] 4  
  Date of Testing: ______________

*Documentation of Metavir stage results must be submitted.*

Approved documentation includes the following options. Requests that do not include one of the approved methods above for Metavir staging, or that do not result in a definitive Metavir stage will be reviewed for acceptance on a case by case basis.

- [ ] A single biopsy *(results must be from the previous 5 years)*
- OR
- [ ] One of the following non-invasive tests *(results must be from the previous 2 years)*:
  - FibroSURE
  - Fibrospect
  - Fibrometer
  - Fibroscan
  - Sheer Wave Elastography.

C. Q80K polymorphism, for Olysio requests: *(Results must be from previous 2 years)*

- [ ] Positive  [ ] Negative  [ ] N/A  
  Date of Testing: ______________

D. NS5A resistance testing in HCV genotype 1a, for Daklinza or Zepatier requests: *(Results must be from previous 2 years)*

- [ ] Positive  [ ] Negative  [ ] N/A  
  Date of Testing: ______________

Results for items E through H, below, must be from the previous 90 days:

E. Child-Turcotte-Pugh Score

- [ ] A (5-6 points)  [ ] B (7-9 points)  [ ] C (10-15 points)

F. Pregnancy Test Results:

- [ ] Positive  [ ] Negative  [ ] N/A  
  Date of Testing: ______________

G. Drug Test Results:

- [ ] Positive  [ ] Negative  [ ] N/A  
  Date of Testing: ______________

H. Has the patient been assessed for hepatitis B virus coinfection?  

- [ ] Yes  [ ] No  
  Date of assessment: __________

  If yes, does the patient require concurrent hepatitis B virus treatment:

- [ ] Yes  [ ] No

4. Prescribing Information:

<table>
<thead>
<tr>
<th>Preferred Hepatitis C Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Direct Acting Antiviral</strong></td>
</tr>
<tr>
<td>Daklinza (daclatasvir)*</td>
</tr>
<tr>
<td>Epclusa (sofosbuvir/velpatasvir)*</td>
</tr>
<tr>
<td><em>Epclusa is preferred for genotypes 2 and 3 only</em></td>
</tr>
<tr>
<td>Technivie (ombitasvir/paritaprevir/ritonavir)</td>
</tr>
<tr>
<td>Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir)</td>
</tr>
<tr>
<td>Viekira XR (ombitasvir/paritaprevir/ritonavir and dasabuvir)</td>
</tr>
<tr>
<td><strong>Other</strong></td>
</tr>
<tr>
<td>PEG-Intron (peginterferon alfa-2b)</td>
</tr>
<tr>
<td>ribavirin capsule/tablet</td>
</tr>
</tbody>
</table>

Non-Preferred Direct Acting Antivirals

- Harvoni (sofosbuvir/ledipasvir)
- Olysio (simeprevir)
- Sovaldi (sofosbuvir)
- Zepatier (elbasvir/grazoprevir)

In the table below, specify all drug(s) being requested in the hepatitis C regimen and indicate the duration of therapy.

<table>
<thead>
<tr>
<th>Requested Drug Name(s)</th>
<th>Requested duration of therapy (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td></td>
</tr>
</tbody>
</table>
Selection of products other than the preferred products above may be appropriate for patients in whom a preferred regimen is not indicated. Request for a product other than a preferred product does not guarantee coverage. If requesting a product other than a preferred product from above, please provide the rational below. **Failure to provide justification may result in denial of prior authorization.**

________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________

5. Required documents for submission for initial prior authorization requests:

- [ ] Completed Initial Request PA Form
- [ ] Completed Prescriber Certification
- [ ] Copy of Metavir fibrosis stage results
- [ ] If applicable, copy of specialist consult

Prescriber Signature: __________________________ Date: __________________________

Prescriber signature indicates provider attests to all information outlined in the Antiviral Agents for Hepatitis C Prior Authorization Form, Prior Authorization Criteria and Policy, and Patient Education for Hepatitis C Treatment Prescriber Certification documents.
Refill Requests:

Initial prior authorization (PA) requests should be completed using the Prior Approval Initial Request section above. Prior authorization must be requested every 6 weeks for therapy continuation. Labs are required for weeks 4 and 12 of therapy. Please review section 1 below for timelines. Failure to provide documentation of labs may result in PA denial.

1. Treatment Information:
   A. Please provide the patient's therapy start date (mm/dd/yy):
   B. Please indicate requested approval period:
      - [ ] Weeks 6 – 12 (week 4 labs due)
      - [ ] Weeks 13 -18
      - [ ] Weeks 19 - 24 (week 12 labs due)
   C. Is the patient compliant with HCV treatment?
      - [ ] Yes
      - [ ] No
   D. Professional judgment shall be used by the prescriber to determine if alcohol or drug tests are needed.
   E. In the table below, specify all drug(s) being requested in the hepatitis C regimen and indicate the total duration of the drug regimen in weeks.

<table>
<thead>
<tr>
<th>Requested Drug Name(s)</th>
<th>Duration of drug regimen (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td></td>
</tr>
</tbody>
</table>

2. Laboratory*:

<table>
<thead>
<tr>
<th>Laboratory Test</th>
<th>Value</th>
<th>Date</th>
<th>Critical values</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT</td>
<td>&gt; 10 x ULN (400 U/L)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scr</td>
<td>&gt; 2 mg/dl</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CrCl</td>
<td>&lt; 30 ml/min/1.73m*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hgb</td>
<td>&lt; 8.5 g/dl</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WBC</td>
<td>&lt; 1,000 cells/µL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANC</td>
<td>&lt; 500 cells/µL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plt</td>
<td>&lt; 25,000 cells/µL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCV RNA level week 4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCV RNA level week 12</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*In certain cases additional labs may be requested.

Prescriber Signature: ___________________________ Date: ___________________________

Confidentiality notice: This communication is intended only for the use of the individual entity to which it is addressed, and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 800.858.0723, and return the original message to Blue Cross and Blue Shield of Texas c/o Prime Therapeutics via U.S. Mail. Thank you for your cooperation.